Clinical Trial Update: Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating olaparib in metastatic urothelial cancer patients with DNA damage response gene alterations has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Cancer

Drugs mentioned

• Olaparib (Olaparib)

Snippet

Sponsor: Matthew Galsky | Conditions: Metastatic Urothelial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-11-22